ClinicalTrials.gg
CompletedNCT06747936Updated Aug 27, 2026

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

A Phase 3 interventional study of AD-2281 and AD-2282 in Primary Hypercholesterolemia, sponsored by Addpharma Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 81 studies in Hypercholesterolemia with a site in Korea, Republic of — 6 open to participants now, 11 under way, 5 of them phase 3. Hypercholesterolemia · Korea, Republic of.

Enrollment
49th of 66
129 · median 251
Started
2025
with 4 others
Phase 3
35 of 81
1 open now
Registered
69th of 81
by date
Lead sponsor
4 of 81
Addpharma Inc.

Among the 81 studies in Hypercholesterolemia with a site in Korea, Republic of, this one is the 49th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2025, is one of 35 in phase 3, and was the 69th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 81 studies in Hypercholesterolemia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Hypercholesterolemia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Patients with Primary Hypercholesterolemia
  • Other inclusions applied

Exclusion criteria

Exclusion Criteria:

  • Patients with Secondary Hypercholesterolemia
  • Other exclusions applied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    AD-2281 + AD-2282

    Drug: AD-2281 · Drug: AD-2282

  • Active comparator
    AD-2281 + Placebo of AD-2282

    Drug: AD-2281 · Drug: Placebo of AD-2282

Interventions

  • DrugAD-2281

    PO, Once daily, 8weeks

  • DrugAD-2282

    PO, Once daily, 8weeks

  • DrugPlacebo of AD-2282

    PO, Once daily, 8weeks

06

What researchers measure

Primary outcomes

  1. Change rate of LDL-C

    Percent change (%) of LDL-C from baseline at week 8

    Time frame: from baseline at 8 weeks

07

Study locations

1 site
  • Severance Hospital
    Seoul, Seoul 03722, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2025, 3 months.

Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 3 months is below that.

Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Dec 24, 2024
StartActual
Feb 3, 2025
Primary completionActual
May 30, 2025
CompletionActual
May 30, 2025
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747936
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Feb 3, 2025
Primary completion
May 30, 2025
Completion
May 30, 2025
Last update
Aug 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion